Guardant Health’s oncology engine kept expanding in Q2, driving total revenue up 44% year over year to $335 million. Oncology revenue grew 38% as oncology test volumes jumped 63%, including a major ramp in colorectal screening for Shield. The company also tied the quarter’s growth to new commercial validation, including an FDA June approval of Guardant360 Liquid CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos in HER2-mutant advanced NSCLC and evolving reimbursement support. Veracyte likewise beat expectations and raised its 2026 revenue outlook after momentum in its Decipher and Afirma oncology franchises. The company cited growth in Decipher prostate prognostics and Afirma thyroid classifier demand, alongside new product launches in the US, including a Prosigna Breast laboratory-developed test and Medicare coverage for its whole-genome sequencing-based TrueMRD Monitoring Test in muscle-invasive bladder cancer. With R&D costs rising, the company’s profit profile improved in Q2. Taken together, the updates underscore how late-stage clinical and reimbursement progress continues to feed growth for liquid biopsy and tissue-based testing platforms. Companies with both regulatory validation and payer traction appear positioned to sustain market share gains as MRD and multimodal strategies move closer to routine care.